rheumatic autoimmune diseases
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In general: willing to give written informed consent. Per group: 1. Patients with rheumatic autoimmune diseases, including rheumatoid arthritis, poly or dermatomyositis, systemic lupus erythematosus, Sjögren*s syndrome, treated with rituximab within 3-9 months prior to start of the study with or without concomitant treatment with traditional DMARDs and/or corticosteroids. 2. Patients with rheumatic autoimmune diseases, including rheumatoid arthritis, poly or dermatomyositis, systemic lupus erythematosus, Sjögren*s syndrome, treated with TNFa blocking agents as single therapy or combined with DMARDs and/or corticosteroids on stable therapy of 3 or more months. 3. Patients with rheumatic autoimmune disease, including rheumatoid arthritis, poly or dermatomyositis, systemic lupus erythematosus, Sjögren*s syndrome, on stable therapy with only traditional DMARDs and/or corticosteroids for 3 or more months. 4. Age and gender matched healthy controls
Exclusion criteria
Exclusion criteria: - Age under 18 years - No informed consent - Pregnancy - History of vaccination allergy - Known allergy to egg products - Patients known with positive hepatitis B serology
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increase in titer of: - Haemagglutination inhibition test for influenza - ELISA for pneumococcal - ELISA for hepatitis B | — |
Secondary
| Measure | Time frame |
|---|---|
| - Potential adverse events - Disease activity | — |
Countries
Netherlands
Outcome results
None listed